Roles for chemokines in liver disease.

By F. Marra, F. Tacke. Gastroenterology, 2014

750 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Liver fibrosis: Pathophysiology, pathogenetic targets and clinical issues. (2019, background): “Another option is to target chemokine-chemokine receptor interactions that sustain recruitment of monocytes, particularly the prominent CCL2-CCR2 interaction (Marra and Tacke, 2014), as shown in murine models using monoclonal antibodies against chemokines or related receptor(s), receptor antagonists”
Hepatic inflammatory responses in liver fibrosis (2023, positive): “Kupffer cells act as intravascular sentinels 72 that sense hepatocyte stress and injury signals from other cells (or extrahepatic sources), engulf cellular debris and can activate inflammatory signals 40,75 .”
Liver Fibrosis: Mechanistic Concepts and Therapeutic Perspectives (2020, background): “Mutual stimulation of inflammatory cells and HSCs results in amplification and perpetuation of the pro-fibrogenic liver state (for a review, see [84]).”
Hepatic fibrosis: Concept to treatment. (2015, background): “Hence, immature Ly6C CD11bF4/80 macrophages and their CCL2dependent accumulation are a central mechanism of fibrosis activation and progression [13].”